Clovis Oncology Inc., of Boulder, Colo., priced an underwritten public offering of 5 million shares of its common stock at $41 each. The size of the offering was upsized from $175 million to $205 million. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock on the same terms and conditions. The company intends to use the net proceeds for general corporate purposes, including the commercial planning and sales and marketing expenses associated with the launch of Rubraca (rucaparib) in the U.S and also in Europe, if approved by the EMA.